Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RMD 1101
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Recipient : Exothera
Deal Size : Undisclosed
Deal Type : Collaboration
Remedium and Exothera Partner On Scale-up And Demonstration Runs For AAV2-FGF18
Details : Remedium and Exothera will demonstrate the industrialization potential of Remedium’s RMD 1101 (AAV2-FGF18). Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for the tr...
Brand Name : RMD 1101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 22, 2023
Lead Product(s) : RMD 1101
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Recipient : Exothera
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : RMD 1101
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Tufts University
Deal Size : Undisclosed
Deal Type : Agreement
Remedium Bio Announces Research Agreement with a Leading Rheumatology Laboratory
Details : Through this partnership, Remedium aims to characterize the functionality of its lead candidate RMD 1101, in a range of in vitro, ex vivo, and in vivo efficacy models that will help to advance it toward IND.
Brand Name : RMD 1101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 15, 2021
Lead Product(s) : RMD 1101
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Tufts University
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?